Form D · Biotechnology
Recourse Biologics, Inc.
Houston, TX · CIK 0002038107
Offering snapshot reported Oct 8, 2024 · SEC filing
- Reported sold
- $2.79M Offering amount: $4.3M
- Investors reported
- 14 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 26, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 8, 2024 | Initial | $2,786,350 | No comparison | 14 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-526186
Source: Form D, filed Oct 8, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Alexander Krupnick | Director |
| Daniel Watkins | Director, Executive |
| John K Westwick | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
3737 Buffalo Speedway Ste 1750
Houston, TX, 77098
Houston, TX, 77098